Comparative Effect of Valsartan and Amlodipine on Serum Lipoproteins (LDL and HDL) Levels among Hypertensive Patients

Introduction: Hypertension is a modifiable risk factor for cardiovascular diseases and is associated with several metabolic disorders like dyslipidemia. Drugs that control blood pressure effectively can increase the potentially atherogenic serum low-density lipoprotein (LDL) cholesterol fraction and triglycerides. In view of the available literature, the present study was undertaken to compare the effect of Valsartan and Amlodipine on LDL and HDL levels among hypertensive patients. Material and Methods: The present study was conducted among fifty patients diagnosed with mild or moderate essential hypertension. Blood pressure was controlled in twenty-five patients with Amlodipine (group A) and twenty-five patients with valsartan (group B) and their adaptation to the treatment was monitored. The patients were monitored for a period of 12 weeks and serum lipoprotiens (HDL, LDL) was carried out at 0 week and then after 12 weeks. Results: Mean serum LDL-Cholesterol level was 146.16±8.12 in the group A and 148.58 ± 6.39 in group B. After 3 months of administration of Amlodipine it was significantly reduced to 127.21±4.29 in group A and after 3 months of administration of Valsartan it was significantly reduced to 142.16 ± 10.05 in group B. Mean serum HDLCholesterol level was nonsignificantly reduced in both the groups. Conclusion: The present study concluded that in addition to the marked decrease in blood pressure, both Valsartan and Amlodipine reported beneficial effect on LDL level and in comparison to Valsartan, Amlodipine reported more beneficial effect on reduction of LDL levels.